Stocktoria

NewcelX Ltd. NCEL

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-01-29

NewcelX Ltd. statistics & valuation

Market cap$19.5M
P / B2.7×
Return on equity-114.5%
Return on capital-35.3%
Graham number +157.4%$8.57

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($8.57); a green figure means the price is below it.

Profitability & efficiency

Gross margin (%)
2019202020212022202320242025
Operating margin (%)
2019202020212022202320242025
Return on equity (%)
-2202.50% -14861.00% -114.50% 2019202020212022202320242025
Shares outstanding
7.0M 7.0M 16.2M 32.4M 35.7M 3.2M 4.8M 2019202020212022202320242025
Net debt ($)
$19419 2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-782.20% -236.20% -207.20% -177.80% -180.40% -797.00% -72.50% 2019202020212022202320242025
Free cash flow margin (%)
2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$0.41 -$1.00 -$33.52 $1.13 $2.43 $2.16 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Return on assets-72.5%-797.0%-180.4%-177.8%-207.2%-236.2%-782.2%
Return on equity-114.5%90.0%278.4%-14861.0%-2202.5%31.9%88.3%
Debt / equity—————-0.01×—
Current ratio0.760.090.232.752.380.030.09

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.